UNAM, Inserm, U922, service de rhumatologie, CHU d'Angers, Angers cedex 9, France.
Joint Bone Spine. 2011 Dec;78(6):568-71. doi: 10.1016/j.jbspin.2011.03.015. Epub 2011 May 17.
Although the existence of atypical femoral fractures is well established and bisphosphonate therapy is thought to be a major risk factor, the underlying mechanisms are poorly understood. Epidemiological data show that atypical femoral fractures account for only a small proportion of diaphyseal subtrochanteric femoral fractures, being about 100 times less common than proximal femoral fractures. Consequently, the existence of atypical femoral fractures does not call into question the extremely favorable risk/benefit ratio of bisphosphonate therapy in patients with osteoporosis. Clearly, the number of fractures prevented by bisphosphonate therapy far exceeds the number of atypical femoral fractures potentially related to bisphosphonates.
虽然非典型股骨骨折的存在已得到证实，并且双膦酸盐治疗被认为是一个主要的危险因素，但其中的机制仍不清楚。 流行病学数据表明，非典型股骨骨折仅占骨干转子下股骨骨折的一小部分，比股骨近端骨折少见约 100 倍。 因此，非典型股骨骨折的存在并没有质疑双膦酸盐治疗骨质疏松症患者的风险/效益比极其有利。 显然，双膦酸盐治疗预防的骨折数量远远超过与双膦酸盐相关的潜在非典型股骨骨折数量。
